Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × niraparib × Lymphoid × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 38 Genitourinary 16 Gastrointestinal 13 Breast 10 Thoracic 8 Other solid neoplasm 6 Head & Neck 5 CNS 5 Tumor-Agnostic 4 Sarcoma 3 Dermatologic 3 Lymphoid 1 Endocrine 1 Classical hematology 1

Conditions

Interventions

Rituximab 686 Cyclophosphamide 610 Vincristine 283 Etoposide 272 Doxorubicin 268 Cytarabine 230 Prednisone 228 Methotrexate 221 fludarabine phosphate 188 Filgrastim 187 Dexamethasone 179 fludarabine 172 Lenalidomide 164 Melphalan 127 Radiotherapy 126 Peripheral Blood Stem Cell Transplantation 123 Busulfan 117 Bendamustine Hydrochloride 114 Granulocyte Colony-Stimulating Factor 113 Bortezomib 112 ibrutinib 111 Mycophenolic Acid 109 Whole-Body Irradiation 105 venetoclax 104 obinutuzumab 104 Tacrolimus 104 Gemcitabine 90 zanubrutinib 80 Specimen Handling 76 Cyclosporine 75

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01244009 2016-11-07

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Tesaro, Inc.

Phase 2 Withdrawn

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡